Pacira BioSciences, Inc.
PCRX
$23.04
$0.200.88%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -9.90% | 9.67% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -9.90% | 9.67% | |||
| Cost of Revenue | -20.49% | 33.61% | |||
| Gross Profit | -6.69% | 4.02% | |||
| SG&A Expenses | -7.54% | 10.69% | |||
| Depreciation & Amortization | 0.00% | 0.00% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -13.27% | 19.73% | |||
| Operating Income | 300.30% | -117.55% | |||
| Income Before Tax | 775.31% | -94.00% | |||
| Income Tax Expenses | 295.31% | -126.05% | |||
| Earnings from Continuing Operations | 78.13% | -69.86% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 78.13% | -69.86% | |||
| EBIT | 300.30% | -117.55% | |||
| EBITDA | 5.80% | -14.95% | |||
| EPS Basic | 87.27% | -68.78% | |||
| Normalized Basic EPS | 170.71% | -124.20% | |||
| EPS Diluted | 81.82% | -67.92% | |||
| Normalized Diluted EPS | 170.87% | -124.14% | |||
| Average Basic Shares Outstanding | -4.78% | -3.51% | |||
| Average Diluted Shares Outstanding | -4.82% | -3.32% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||